A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors With an Expansion Cohort in HIV Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 30 Sep 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
Indications Adenocarcinoma; Anal cancer; Colon cancer; Gallbladder cancer; Hodgkin's disease; Kaposi's sarcoma; Lung cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions

20 Sep 2024 According to ClinicalTrials.gov: US National Institutes of Health record, this trial is terminated due to Inadequate accrual rate
20 Sep 2024 Status changed from active, no longer recruiting to discontinued.
19 Sep 2024 Planned End Date changed from 30 Aug 2024 to 13 Sep 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com